A muted start to the morning but hopefully we can build on some of the positive momentum from yesterday. It seems to me that the sector wants to get to that $130 level where it should be some resistance. I think that level is important in the near term but longer term it is that […]
A good morning so far. It is certainly nice to see and ideally this is where we start to build some momentum. We seem to have had countless false starts but if you take a step back it almost looks as if this entire year (since about March) has been a range between $120 and […]
Well, this week is not a disaster and that is positive. We have not built any momentum to the upside but we also do not seem on the verge of breaking down. We are inching closer to a seasonally positive period for the sector and so treading water and forming a base is not bad. […]
Still fall break with the kids, so I will try and keep this focused. The sector is off to a good start this week and it is hard to know if this is simply following the broader market, a bounce from support, or a move from some positive news. It is likely a little of […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.